Financial Performance - The company achieved a revenue of 242.09 million yuan in the first half of 2025, representing a year-on-year growth of 14.93% [2] - Net profit attributable to shareholders was 60.79 million yuan, with a year-on-year increase of 4.74% [2] - The gross profit margin improved by 3.56 percentage points compared to the same period last year, reaching 29.24% [2][4] International Market Expansion - Overseas sales increased by 53.04%, contributing to 55.61% of total revenue [3][6] - The company has participated in international exhibitions for over 20 years, expanding its presence in markets such as Europe, India, and Brazil, and plans to enter more countries [3] - The company aims to strengthen its position in existing markets like India, Mexico, and Brazil while increasing investments in the US and Europe [3] Sales and Market Strategy - The sales of raw materials and intermediates grew by 13.94% and 29.24% respectively, driving overall performance [5][12] - The company has optimized its production capacity to ensure stable supply and has adjusted sales strategies to meet market demand [5][11] - The company is focused on maintaining long-term relationships with strategic partners, enhancing management levels, and expanding its customer base [9][14] Research and Development - R&D expenses amounted to 17.71 million yuan, accounting for 7.32% of revenue, with a year-on-year increase of 52.83% [10] - The company has 17 ongoing R&D projects, including products for antiviral and anti-inflammatory treatments [10] - A new pilot workshop is being established to facilitate the industrialization of R&D outcomes [10] Asset Growth and Investment - Total assets increased by 2.61% compared to the beginning of the period, while net assets attributable to shareholders grew by 4.03% [5] - The company is advancing the construction of a new green and intelligent pharmaceutical production base to enhance production capacity [5][11] Cost Management - Total operating costs were 172.70 million yuan, up 18.86% year-on-year, with management expenses rising by 29.34% [8] - The company emphasizes cost control through process optimization and expenditure management [8] Shareholder Returns - The company approved a profit distribution plan in April 2025, which includes a cash dividend of 1.70 yuan per 10 shares and a capital reserve increase of 4.8 shares per 10 shares [9] - Future dividend policies will be based on operational performance and cash flow [21]
海森药业(001367) - 投资者关系活动记录表（2025年半年度网上业绩说明会）